November 30, 2026

   

12:00-1:00 p.m. China Standard Time

Fast-Tracking ATMP First-in-Human Trials: Hong Kong's Patient-First Advantage

Planning a first-in-human cell or gene therapy trial brings scientific and patient care considerations into close focus: What safety evidence is needed before the study begins? How will clinical teams recognise and manage potential complications? What needs to be in place for long-term patient follow-up?

Join Novotech and leading Hong Kong clinical research experts to explore these questions through local investigators’ experience. The discussion will examine the preclinical evidence, specialist expertise and site capabilities sponsors should assess when considering Hong Kong for an advanced therapy medicinal product (ATMP) first-in-human trial, alongside planning for global development.

What You’ll Learn:

  • How Hong Kong investigators and multidisciplinary teams prepare to identify and manage ATMP-related complications.
  • What sponsors should consider when preparing preclinical safety evidence for ethics, scientific committee and Department of Health review, and how early site engagement can support submission planning.
  • Investigators’ experience with patient recruitment and the infrastructure available to support long-term follow-up.
  • Considerations for using Hong Kong-generated trial data in global submissions, and local resources available to help sponsors navigate the clinical trial ecosystem.

Speakers

  • Professor SINGH Gill Harinder Harry, Clinical Associate Professor
  • Professor YUEN Man Fung J.P., Deputy Department Chairperson, Chair Professor and Chief of Division of Gastroenterology and Hepatology
  • Bernard Cheung, CEO, Greater Bay Area International Clinical Trial Institute
  • Chris Chong, Senior Director Clinical Services, Clinical Operations, Novotech

Register now:

Fast-Tracking ATMP First-in-Human Trials: Hong Kong's Patient-First Advantage